Crystallization and preliminary X-ray diffraction analysis of the multidrug efflux transporter NorM from Neisseria gonorrhoeae by Su, Chih-Chia et al.
Physics and Astronomy Publications Physics and Astronomy
2008
Crystallization and preliminary X-ray diffraction
analysis of the multidrug efflux transporter NorM
from Neisseria gonorrhoeae
Chih-Chia Su
Iowa State University, jacksu@iastate.edu
Feng Long
Iowa State University
Gerry McDermott
University of California - Berkeley
William M. Shafer
Emory University
Edward Yu
Iowa State University, ewyu@iastate.edu
Follow this and additional works at: http://lib.dr.iastate.edu/physastro_pubs
Part of the Biochemistry Commons, Biological and Chemical Physics Commons, Medicinal-
Pharmaceutical Chemistry Commons, and the Other Biochemistry, Biophysics, and Structural
Biology Commons
The complete bibliographic information for this item can be found at http://lib.dr.iastate.edu/physastro_pubs/171. For information on how to cite this
item, please visit http://lib.dr.iastate.edu/howtocite.html.
This Article is brought to you for free and open access by the Physics and Astronomy at Iowa State University Digital Repository. It has been accepted
for inclusion in Physics and Astronomy Publications by an authorized administrator of Iowa State University Digital Repository. For more information,
please contact digirep@iastate.edu.
Crystallization and preliminary X-ray diffraction analysis of the multidrug
efflux transporter NorM from Neisseria gonorrhoeae
Abstract
The crystallization and preliminary X-ray data analysis of the NorM multidrug efflux pump produced by
Neisseria gonorrhoeae are reported. NorM is a cytoplasmic membrane protein that consists of 459 amino-acid
residues. It is a member of the recently classified multidrug and toxic compound extrusion (MATE) family of
transporters and recognizes a number of cationic toxic compounds such as ethidium bromide, acriflavin, 2-N-
methylellipticinium and ciprofloxacin. Recombinant NorM protein was expressed in Escherichia coli and
purified by metal-affinity and gel-filtration chromatography. The protein was crystallized using hanging-drop
vapor diffusion. X-ray diffraction data were collected from cryocooled crystals at a synchrotron light source.
The best crystal diffracted anisotropically to 3.8 Å and diffraction data were complete to 6.5 Å resolution. The
space group was determined to be C2, with unit-cell parameters a = 81.5, b = 164.4, c = 111.5 Å.
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The crystallization and preliminary X-ray data analysis of the NorM multidrug
efflux pump produced by Neisseria gonorrhoeae are reported. NorM is a
cytoplasmic membrane protein that consists of 459 amino-acid residues. It is a
member of the recently classified multidrug and toxic compound extrusion
(MATE) family of transporters and recognizes a number of cationic toxic
compounds such as ethidium bromide, acriflavin, 2-N-methylellipticinium and
ciprofloxacin. Recombinant NorM protein was expressed in Escherichia coli and
purified by metal-affinity and gel-filtration chromatography. The protein was
crystallized using hanging-drop vapor diffusion. X-ray diffraction data were
collected from cryocooled crystals at a synchrotron light source. The best crystal
diffracted anisotropically to 3.8 A˚ and diffraction data were complete to 6.5 A˚
resolution. The space group was determined to be C2, with unit-cell parameters
a = 81.5, b = 164.4, c = 111.5 A˚.
1. Introduction
Gonorrhea is one of the most common sexually transmitted diseases
in the world. It is estimated that 800 000 cases of gonorrhea occur
annually in the USA at a cost of $1.1 billion (http://www.thebody.com/
content/art6532.html). The disease is caused by the Gram-negative
bacterium Neisseria gonorrhoeae, which is increasingly resistant to
most inexpensive antibiotics, including penicillin, tetracycline,
erythromycin and ciprofloxacin. In April 2007, the Centers for
Disease Control and Prevention (CDC) officially added gonorrhea to
the list of antibiotic-resistant ‘superbugs’ (http://www.cdc.gov/std/
Gonorrhea/STDFact-gonorrhea.htm). Since N. gonorrhoeae is a strict
human pathogen and can colonize male and female genital mucosal
surfaces and other sites, it has developed mechanisms to overcome
the host antimicrobial systems that are essential to innate host
defense (Shafer et al., 2001). One important mechanism that N.
gonorrhoeae uses to subvert antimicrobial agents is the expression of
multidrug efflux transporters. These transporters recognize and
actively export a wide variety of structurally unrelated toxic
compounds, including antibacterial peptides, long-chain fatty acids
and several clinically useful antibiotics, from the bacterial cell (Lee &
Shafer, 1999; Shafer et al., 1998, 2001; Rouquette-Loughlin et al.,
2003).
Four efflux transporters have been identified in N. gonorrhoeae.
One such transporter is the MtrD inner membrane protein (Hagman
et al., 1997), which exists as a component of the tripartite resistance
nodulation cell division (RND) efflux pump (Tseng et al., 1999). This
pump mediates the export of hydrophobic antimicrobial agents
including antibiotics, nonionic detergents, certain antibacterial pep-
tides, bile salts and gonadal steroid hormones from the bacterium
(Shafer et al., 1998; Delahay et al., 1997; Hagman et al., 1995, 1997).
The FarB transporter (Lee & Shafer, 1999), which belongs to the
major facilitator (MF) family (Griffith et al., 1992; Marger & Saier,
1993; Pao et al., 1998), recognizes antibacterial long-chain fatty acids
and exports them out of the cell. MacB has recently been described
(Rouquette-Loughlin et al., 2005) and belongs to the ATP-binding
cassette (ABC) transporter family (Higgins, 1992). It is poorly
expressed in wild-type gonococci owing to a natural mutation in its
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promoter, but can recognize and export certain macrolide antibiotics.
Finally, N. gonorrhoeae contains the NorM multidrug transporter
(Rouquette-Loughlin et al., 2003), which is a member of the most
recently classified multidrug and toxic compound extrusion (MATE)
family of efflux pumps (Rouquette-Loughlin et al., 2003; Brown et al.,
1999; Morita et al., 1998). As a multidrug efflux pump, the gonococcal
NorM appears to recognize a number of cationic toxic compounds
such as ethidium bromide, acriflavin, 2-N-methylellipticinium and
ciprofloxacin (Rouquette-Loughlin et al., 2003). We recently deter-
mined that NorM binds a variety of structurally dissimilar agents in
the micromolar range and behaves as an Na+-dependent transporter
(Long et al., 2008). The capacity of NorM to export the antibiotic
ciprofloxacin is recognized as being clinically relevant in the devel-
opment of fluoroquinolone resistance in N. gonorrhoeae.
The MATE transporters characteristically possess 12 putative
transmembrane domains. To date, the overall properties of the
MATE family of proteins have not been completely determined and
no structural models are available for this type of multidrug resis-
tance-conferring protein. As an initial step to elucidate the structural
basis of multidrug recognition and extrusion by NorM, we here report
the crystallization and preliminary X-ray diffraction analysis of the
NorM transporter.
2. Cloning, expression and purification
2.1. Cloning
Recombinant full-length NorM containing a 6His tag directly
attached to the C-terminal end (C-6His) was produced in Escher-
ichia coli TOP10 cells using the pBAD vector (Invitrogen). The
cloning and expression procedures have been described previously
(Long et al., 2008). This recombinant C-6His NorM is fully func-
tional in vivo and the purified protein has been demonstrated to bind
antimicrobials in a detergent environment with dissociation constants
spanning the micromolar range (Long et al., 2008).
To produce recombinant full-length NorM containing a 6His tag
at the N-terminus, the ORF for norM from the genomic DNA of
N. gonorrhoeae strain FA19 was amplified by PCR using the primers
50-AAACATATGCTGCTCGACCTCGACCGC-30 and 50-AAAG-
GATCCTCAGACGGCCTTGTGTGATTTGC-30. The 1380 bp PCR
fragment of the norM gene with flanking sequences was extracted
from the agarose gel using a gel-extraction kit (Qiagen) and then
digested with NdeI and BamHI (New England Biolabs). The digested
products were ligated into the pET15b expression vector (Novagen)
to generate a recombinant protein that contains a 6His tag, a
thrombin-cleavage site and a three-residue (GSH) N-terminal spacer
attached to the N-terminal end of NorM (N-6His). The sequence of
this N-6His NorM protein is MGSSHHHHHHSSGLVPRGSH-
NorM. This recombinant plasmid (pET15bnorM) was transformed
into DH5 cells and selected on LB plates containing 100 mg ml1
ampicillin. The construction was verified by DNA sequencing.
2.2. Protein expression
The C-6His NorM protein was overproduced in E. coli TOP10/
pBADnorM cells as described elsewhere (Long et al., 2008). As
these cells cannot be grown in M9 minimal media, recombinant
selenomethionyl-NorM (SeMet-NorM) protein was overproduced
using the N-6His construct in E. coli B834/pET15norM cells.
Briefly, a 10 ml overnight culture in Luria–Bertani (LB) broth was
transferred into 120 ml LB broth containing 100 mg ml1 ampicillin.
The culture was grown with shaking (210 rev min1) at 310 K. When
the OD600 value reached 1.2, cells were harvested by centrifugation at
6000 rev min1 for 10 min and then washed two times with 20 ml M9
minimal salts solution. The cells were resuspended in 120 ml M9
media and then transferred into 12 l pre-warmed M9 solution
containing 100 mg ml1 ampicillin. The cell culture was incubated at
310 K with shaking. When the OD600 reached 0.4, 60 mg l
1 l-
selenomethionine was added. The culture was then induced with
1 mM isopropyl -d-1-thiogalactopyranoside (IPTG) after 15 min.
Cells were harvested within 3 h and were frozen and stored at 193 K.
2.3. Protein purification
The C-6His NorM protein was purified using an Ni2+-affinity
column as described in Long et al. (2008), followed by a G-200 sizing
column to enhance purity. This step was also essential to exchange
n-dodecyl--d-maltoside (-DDM) with different detergents for
crystallization attempts. The procedure for detergent exchange using
gel-filtration chromatography was as follows: the purified C-6His
NorM protein in buffer containing 20 mM Na HEPES pH 7.5 and
0.1% -DDM was concentrated to a volume of 800 ml (10 mg ml1)
using a YM-100 concentrator (Millipore, 100 kDa molecular-weight
cutoff). The concentrated protein was then loaded onto a Superdex
200 (G-200) 16/60 column (Amersham Pharmacia Biotech) pre-
equilibrated with buffer containing 20 mMNa HEPES pH 7.5 and the
relevant detergent at the described concentration. The volume and
length of the G-200 sizing column were 120 ml and 60 cm, respec-
tively. A flow rate of 0.5 ml min1 was used and 2 ml fractions were
collected and analyzed by 10% SDS–PAGE.
The purification procedures for the N-6His SeMet-NorM protein
were similar to those used for C-6His NorM. In brief, the N-6His
SeMet protein was purified using an Ni2+-affinity column as described
in Long et al. (2008). The purified protein was extensively dialyzed
against buffer containing 20 mM Na HEPES pH 7.5 and 0.1%
-DDM, concentrated to 2 mg ml1 and then incubated for 24 h at
298 K in the presence of one unit of thrombin per 2 mg protein to
cleave the hexahistidine tag. After thrombin cleavage, the newly
formed SeMet-NorM protein, which contained a three-residue
spacer, GSH, directly attached to the N-terminus (GSH-SeMet-
NorM), was loaded onto a G-200 sizing column pre-equilibrated with
buffer containing 20 mM Na HEPES pH 7.5 and 0.1% -DDM for
further purification. The purity of the purified GSH-SeMet-NorM
protein was judged using 10% SDS–PAGE stained with Coomassie
Brilliant Blue. NorM is a 459-amino-acid protein that contains 19
methionines. Replacement of these methionine sulfurs with sele-
niums in the GSH-SeMet-NorM protein was confirmed by MALDI
time-of-flight mass spectrometry.
Both the C-6His NorM and GSH-SeMet-NorM proteins were
concentrated to 20 mg ml1 in solution containing 20 mMNa HEPES
pH 7.5 and 0.1% -DDM. Typical starting and ending volumes were
10 ml and 300 ml, respectively. To avoid concentrating -DDM in the
protein solution, a YM-100 Centriprep concentrator (Millipore,
100 kDa molecular-weight cutoff) was used for protein concentration.
The 100 kDa molecular-weight cutoff concentrators have been shown
to be efficient enough to avoid concentrating the -DDM micelles
(Urbani & Warne, 2005).
3. Crystallization
3.1. Detergents
The full-length C-6His NorM protein containing six histidines at
the C-terminus was crystallized in 24-well plates using the hanging-
drop vapor-diffusion method. Initial crystallization trials using
commercially available screening kits, including Hampton Crystal
crystallization communications
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Screens I, II and Lite, PEG/Ion and MembFac, failed. Accordingly,
we performed crystallization screening by mixing different poly-
ethylene glycols [PEGs; ranging from PEG 200 to PEG 20 000 and
PEG 550 MME (monomethyl ether) to PEG 5500 MME] with
different buffers (between pH 3.5 and pH 9.5), salts, additives and
detergents. The experiments were performed at 277 or 298 K.
Initially, five different detergents, -DDM, n-dodecyl--d-malto-
side (-DDM), polyoxyethylene(8)dodecyl ether (C12E8), n-undecyl-
-d-maltoside (UDM), n-tetradecyl--d-maltoside (TDM) and
n-octyl--d-glucoside (OG), were used as primary detergents in our
crystallization trials. The experiments suggested that protein solution
containing 0.1% -DDM or 0.8% OG resulted in the formation of
protein crystals. Crystals grown in the presence of -DDM diffracted
to 8 A˚; however, those grown in the presence of OG did not diffract
X-rays. Thus, -DDMwas chosen as the primary detergent for further
crystallization trials.
We attempted to improve the quality of the crystals by searching
for a suitable secondary detergent using Detergent Screens 1, 2 and 3
(Hampton Research). After the initial screen, eight different
secondary detergents, C12E8, UDM, polyoxyethylene(9)dodecyl ether
(C12E9), 6-cyclohexyl-1-hexyl--d-maltoside (Cymal-6), n-decyl-
-d-maltoside (DM), n-dodecylphosphocholine (Fos-choline-12),
n-nonyl--d-glucoside (NG) and 3-(3-butyl-3-phenylheptanamido)-
N,N-dimethylpropan-1-amine oxide (TRIPAO), were chosen for
further trials. However, it appeared that the addition of these
secondary detergents did not improve the diffraction limit of the
crystals.
3.2. Removal of hexahistidine tags
We then created a thrombin-cleavage site at position 454 of the
protein in order to remove the hexahistidine tag at the C-terminus of
C-6His NorM. After removing the 6His tag, this NorM protein
(NorM454, amino acids 1–454) was purified in -DDM and subjected
to a broad screen with various PEGs, salts, buffers, additives and
detergents as described above. Unfortunately, crystals of the
NorM454 protein diffracted X-rays in a similar manner to those of
C-6His NorM and did not appear to enhance the resolution limit.
We also attempted to improve the crystal quality by crystallizing
N-6His NorM. After the removal of the 6His tag using thrombin,
this NorM protein, GSH-NorM, containing a three-residue spacer
(GSH) at the N-terminal end, was screened with various PEGs, salts,
buffers, additives and detergents as above. However, the best crystal
obtained was no better than that obtained for C-6His NorM. We
thus focused our subsequent crystallization efforts on the C-6His
NorM protein.
3.3. Crystallization conditions
For hanging-drop vapor diffusion, a 2 ml drop consisting of 1 ml
protein solution (20 mg ml1 NorM in 20 mM Na HEPES pH 7.5 and
0.1% -DDM) and 1 ml reservoir solution was equilibrated against
500 ml reservoir solution. The initial crystals of NorM were grown in
15–18% PEG 1000 and 20–100 mM Na HEPES pH 7.5. After opti-
mization, the best C-6His NorM crystals were obtained at 298 K
from well solution containing 16% PEG 1000, 40 mM Na HEPES
buffer pH 7.5 and 4% glycerol. Crystals appeared within one week
and typically had dimensions of about 200  200  200 mm. Fig. 1
illustrates a typical native crystal of C-6His NorM. Cryoprotection
was achieved by raising the PEG 1000 concentration stepwise to 26%
in 5% increments. Crystals of the GSH-SeMet-NorM protein (after
removal of the 6His tag at the N-terminus) were grown under the
same conditions.
4. Data collection and processing
For data collection, a single native crystal of C-6His NorM was
flash-cooled in a cryoprotectant solution containing 26% PEG 1000,
40 mM Na HEPES buffer pH 7.5 and 4% glycerol at 100 K. The best
crystal diffracted anisotropically to a resolution of 3.8 A˚. Fig. 2
depicts one of the diffraction images of the native NorM crystal.
Single-wavelength anomalous diffraction data were collected at the
peak wavelength from a single GSH-SeMet-NorM crystal. The best
native C-6His NorM and GSH-SeMet-NorM diffraction data were
obtained to resolutions of 6.5 and 7.2 A˚, respectively (Table 1).
Diffraction data sets were obtained from the native C-6His
NorM crystals at the Advanced Photon Source (APS, beamline
24IDC) at cryogenic temperature (100 K) using an ADSC Quantum
315 CCD-based detector. The beam size was 50 20 mm. Data for the
GSH-SeMet-NorM crystals were obtained at the Advanced Light
Source (ALS, beamline 8.2.2) at cryogenic temperature (100 K) using
crystallization communications
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Figure 1
N. gonorrhoeae C-6His NorM crystal. The dimensions of the crystal are
approximately 200  200  200 mm.
Figure 2
X-ray diffraction pattern of the native C-6His NorM crystal. The crystal
diffracted anisotropically to a resolution beyond 3.8 A˚.
an ADSC Quantum 315 CCD-based detector. The beam size was
140  150 mm. Diffraction data sets were processed with DENZO
and scaled with SCALEPACK (Otwinowski & Minor, 1997). The
native C-6His NorM crystal belonged to space group C2, with unit-
cell parameters a = 81.5, b = 164.4, c = 111.5 A˚. The GSH-SeMet-
NorM crystal belonged to the same space group with very similar
unit-cell parameters (Table 1). Based on the molecular weight of the
C-6His NorM protein (50.6 kDa, including the 6His tag at the C-
terminus) and the volume of the asymmetric unit, the Matthews
parameters (Matthews, 1968, 1977) for one and two molecules of
NorM in the asymmetric unit were found to be 7.0 and 3.5 A˚3 Da1,
respectively. This suggests the presence of one or two NorM mole-
cules per asymmetric unit, with solvent contents of 82.2% or 64.4%,
respectively.
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Table 1
Data collection and crystallographic analysis of NorM.
Vaues in parentheses are for the highest resolution shell.
Native C-6His NorM GSH-SeMet-NorM (peak)
Wavelength (A˚) 0.9795 0.9795
Space group C2 C2
Unit-cell parameters (A˚) a = 81.5, b = 164.4, c = 111.5 a = 82.5, b = 164.8, c = 113.7
Resolution (A˚) 6.49 (8.18–6.49) 7.15 (7.43–7.15)
Completeness (%) 99.6 (90.8) 99.4 (92.3)
Total No. of reflections 305366 179056
No. of unique reflections 14522 11967
Rmerge (%) 7.8 (28.2) 8.3 (34.7)
Average I/(I) 14.1 (3.4) 22.3 (4.9)
